The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), significantly improving access to diabetes

The FDA has approved the first generic form of liraglutide (Victoza), a once-daily injectable for improving glycemic control in patients ages 10 and older with type 2 diabetes, used as an adjunct to diet and exercise.

Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug Administration. Compounded copycat drugs containing tirzepatide, many sold by online pharmacies, will no longer be allowed.